SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · Rhythm Pharmaceuticals presented positive clinical and real-world data…

Rhythm Pharmaceuticals, Inc. · PRESS-RELEASE filed Jun 15, 2026 at 16:01 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 15, 2026 at 16:01 ET

Rhythm Pharmaceuticals presented positive clinical and real-world data at ENDO 2026 for setmelanotide and bivamelagon across multiple rare obesity indications (acquired hypothalamic obesity, BBS, PWS). The data showed sustained weight loss, hunger reduction, and improved healthcare utilization, reinforcing the commercial thesis for its MC4R agonist platform. The stock market reaction is likely muted as the data is incremental and consistent with prior disclosures, but the breadth of positive readouts across indications supports the long-term pipeline value.

  • Setmelanotide achieved -18.9% mean BMI reduction at 2.5 years in acquired HO patients (n=11).
  • Oral bivamelagon showed -8.7% to -16.6% BMI reduction at 1 year across dose cohorts (n=26).
  • 71.1% of pediatric and 71.4% of adult acquired HO patients achieved ≥1 weight category improvement with setmelanotide vs 13.6% and 6.7% on placebo.
  • Real-world BBS data (n=286): 62% of adults achieved ≥10% body weight loss at 12 months; mean -9.8% weight loss in adults.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access